Astera Labs, Inc. $ALAB Shares Bought by Fortis Capital Advisors LLC

Key Points

• Fortis Capital Advisors boosted its stake in Astera Labs by 71% in Q4 to 18,156 shares, valued at about $3.02 million.
• Astera Labs delivered a strong quarter, posting EPS of $0.58 (vs. $0.51 est.) and revenue of $270.6M (vs. $249.5M est.), up 91.8% year‑over‑year, and guided Q1 to $0.530–$0.540 EPS.
• Significant insider selling occurred recently—704,009 shares (~$88.5M) sold over the past 90 days—while institutional investors own roughly 60.5% of the company and insiders about 12.5%.

Fortis Capital Advisors LLC increased its position in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 71.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,156 shares of the company's stock after acquiring an additional 7,537 shares during the period. Fortis Capital Advisors LLC's holdings in Astera Labs were worth $3,020,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Nordea Investment Management AB bought a new position in Astera Labs during the 4th quarter valued at $2,028,000. Geneva Partners LLC purchased a new position in Astera Labs in the 3rd quarter worth about $1,876,000. Numerai GP LLC boosted its holdings in shares of Astera Labs by 153.1% in the third quarter. Numerai GP LLC now owns 13,212 shares of the company's stock worth $2,587,000 after buying an additional 7,992 shares during the period. Handelsbanken Fonder AB boosted its holdings in shares of Astera Labs by 289.5% in the third quarter. Handelsbanken Fonder AB now owns 126,200 shares of the company's stock worth $24,710,000 after buying an additional 93,800 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in shares of Astera Labs in the second quarter worth about $543,000. Institutional investors and hedge funds own 60.47% of the company's stock.

Trending Headlines about Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Earnings beat, revenue growth and guidance support momentum — Astera Labs reported a sizable revenue beat and higher EPS with raised Q1 guidance, which underpins investor confidence and several buy/outperform analyst ratings. Astera Labs Trading Up 1.9%
• Positive Sentiment: Insider alignment highlighted in growth stock roundups — recent articles that spotlight growth companies with meaningful insider ownership include Astera Labs, reinforcing a narrative that management holds large stakes and is aligned with shareholders. April 2026's Top Growth Companies With Strong Insider Ownership
• Neutral Sentiment: Market commentary on today’s move — coverage from market sites notes ALAB outpaced the broader market on the latest session; useful context but largely descriptive rather than new fundamental news. Why Astera Labs, Inc. (ALAB) Outpaced the Stock Market Today
• Neutral Sentiment: Institutional ownership and analyst coverage — institutional investors hold a majority stake and several firms have set price targets above current levels; this provides stability but also mixed target ranges. Astera Labs Trading Up 1.9%
• Negative Sentiment: CEO share sales — CEO Jitendra Mohan sold 2,967 shares (~$174.60 avg) on April 15 under a pre-arranged Rule 10b5-1 plan; recent prior sales mean continued insider liquidity, which some investors view as a modest negative despite plan safeguards. Astera Labs NASDAQ: ALAB CEO Sells $518,038.20 in Stock
• Negative Sentiment: Competitive comparison with Amphenol — analyst pieces comparing ALAB to larger, diversified peers (e.g., Amphenol) suggest APH may present a less risky exposure in data-infrastructure, which could cap upside for ALAB until market share or diversification improves. Amphenol vs. ALAB: Which Data Infrastructure Stock Should You Buy?

Insider Buying and Selling at Astera Labs

In other news, Director Jack R. Lazar sold 2,500 shares of Astera Labs stock in a transaction on Monday, March 16th. The stock was sold at an average price of $130.00, for a total transaction of $325,000.00. Following the completion of the sale, the director owned 84,851 shares of the company's stock, valued at approximately $11,030,630. This trade represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael Truett Tate sold 12,001 shares of the business's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total value of $1,485,843.81. Following the completion of the transaction, the chief financial officer directly owned 192,083 shares of the company's stock, valued at approximately $23,781,796.23. This trade represents a 5.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 704,009 shares of company stock worth $88,536,187. 12.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on ALAB shares. Barclays set a $165.00 price objective on shares of Astera Labs in a research report on Thursday, January 15th. Citigroup started coverage on shares of Astera Labs in a research report on Thursday, April 2nd. They set a "buy" rating and a $200.00 target price on the stock. Loop Capital initiated coverage on Astera Labs in a research note on Thursday, March 5th. They issued a "buy" rating and a $250.00 target price for the company. Weiss Ratings lowered shares of Astera Labs from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, February 23rd. Finally, Royal Bank Of Canada initiated coverage on shares of Astera Labs in a report on Wednesday, January 14th. They issued an "outperform" rating and a $225.00 price target on the stock. Fifteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $199.44.

Astera Labs Stock Performance

NASDAQ ALAB opened at $174.05 on Monday. The business has a 50 day simple moving average of $129.83 and a 200 day simple moving average of $153.79. Astera Labs, Inc. has a 52-week low of $52.56 and a 52-week high of $262.90. The stock has a market cap of $29.81 billion, a price-to-earnings ratio of 142.66, a PEG ratio of 3.42 and a beta of 1.78.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.07. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The company had revenue of $270.58 million during the quarter, compared to analysts' expectations of $249.46 million. During the same period last year, the business earned $0.37 EPS. The business's quarterly revenue was up 91.8% on a year-over-year basis. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.